A Phase 1 Trial of RP1: A New Oncolytic Virus Alone and in Combination with Nivolumab
Middleton M. et al, (2020), ANNALS OF SURGICAL ONCOLOGY, 27, S132 - S132
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Gupta A. et al, (2020), Br J Cancer, 122, 506 - 516
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Garbe C. et al, (2020), Eur J Cancer, 126, 159 - 177
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.
Garbe C. et al, (2020), Eur J Cancer, 126, 141 - 158
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
Fairfax BP. et al, (2020), Nat Med, 26, 193 - 199
Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.
Peach H. et al, (2020), J Plast Reconstr Aesthet Surg, 73, 36 - 42
Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?
Cheung VTF. et al, (2020), JOURNAL OF CROHNS & COLITIS, 14, S286 - S288
DEBIOC: A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma
Thomas A. et al, (2019), European Journal of Cancer
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG. et al, (2019), Ann Oncol, 30, 2013 - 2014
Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
Findlay JM. et al, (2019), Eur Radiol, 29, 6717 - 6727
The T-cell architecture of pancreatic ductal adenocarcinoma
Sivakumar S. et al, (2019), CANCER RESEARCH, 79
Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma
Shoushtari A. et al, (2019), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7
Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors
Middleton M. et al, (2019), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7
Neurocognitive outcomes in a phase-3 randomised trial comparing adjuvant whole brain radiotherapy with observation after local treatment of brain metastases in patients with melanoma
Dhillon H. et al, (2019), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, 99 - 100
Phase-3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs)
Fogarty GB. et al, (2019), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, 100 - 101
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Weber JS. et al, (2019), ANNALS OF ONCOLOGY, 30, 533 - +
Early peripheral T-cell responses predict oncological outcome to checkpoint immune blockade in metastatic melanoma
Fairfax B. et al, (2019), ANNALS OF ONCOLOGY, 30
Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study
Middleton MR. et al, (2019), ANNALS OF ONCOLOGY, 30
Identification of transcriptomic markers predictive of clonal response to checkpoint inhibitor treatment
Watson RA. et al, (2019), EUROPEAN JOURNAL OF IMMUNOLOGY, 49, 1744 - 1745
Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Dalle S. et al, (2019), ANNALS OF ONCOLOGY, 30